Sinovac Biotech Ltd, a leading provider of biopharmaceutical products in China, announced that it has officially filed for conditional market authorisation for CoronaVac, the COVID-19 vaccine, with China’s National Medical Products Administration (NMPA).

The vaccine candidate was tested in phase III clinical studies outside of China. The preliminary results of the trials demonstrated a good safety profile for the vaccine. Fourteen days after a two-dose vaccination, the efficacy rate meets the standards of the World Health Organization (WHO) and the guiding principles for Clinical Evaluation on Preventive COVID-19 Vaccine (tentative) issued by the NMPA.

This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.

This announcement contains forward-looking information about the Company’s efforts to develop a potential COVID-19 vaccine that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.